ReviewNature reviews. Rheumatology2011
Sarcoidosis--scientific progress and clinical challenges.
Review in Nature reviews. Rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 189 citations in OpenAlex.
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.Molecular medicine (Cambridge, Mass.) · 2013Trial
- Cardiac Sarcoidosis: A Practical Guide for Cardiologists.Current cardiology reports · 2026Review
- Sarcoidosis: A Clinical Trials Perspective.Pulmonary therapy · 2026Review
- Altered Thiol-Disulfide Homeostasis in Sarcoidosis: A Case-Control Study.Medicina (Kaunas, Lithuania) · 2026Article
- Hepatic Sarcoidosis Unmasked by Chronic Pruritus and Esophageal Varices: A Case Report.Clinical case reports · 2026Article
- Neurological involvement and pregnancy outcomes in autoimmune disease: mechanisms, clinical implications, and research gaps.Rheumatology international · 2026Review
- The diagnosis dilemma of coexistence of neurosarcoidosis and tuberculosis: case reports and literature review.Frontiers in medicine · 2026Article
- Immunopathogenesis of Sarcoidosis.Seminars in respiratory and critical care medicine · 2025Review
- Serum metabolic disparity between patients with lymph node tuberculosis and patients with sarcoidosis: towards differential diagnosis.BMC pulmonary medicine · 2025Article
- Shifting temporal trends and disparities in sarcoidosis mortality in the United States: A retrospective analysis from 1999 to 2020.PloS one · 2025Article
- Sarcoidosis and Cancer: The Role of the Granulomatous Reaction as a Double-Edged Sword.Journal of clinical medicine · 2024Article
- Microblading reaction as a manifestation of systemic sarcoidosis: two case reports and a review of the literature.Journal of medical case reports · 2024Review
- Article
- Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.Journal of clinical medicine · 2023Review
- Examination of eQTL Polymorphisms Associated with Increased Risk of Progressive Complicated Sarcoidosis in European and African Descent Subjects.European journal of respiratory medicine · 2023Article
- Sarcoidosis mimicking nodal manifestations of marginal zone lymphoma.European journal of nuclear medicine and molecular imaging · 2023Article
- Increased incidence of thyroid disease in patients with sarcoidosis: a systematic review and meta-analysis.Endocrine connections · 2023Article
- Whipple's Disease Mimicking Sarcoidosis.Cureus · 2023Article
- The Overlap of Kidney Failure in Extrapulmonary Sarcoidosis in Children-Case Report and Review of Literature.International journal of molecular sciences · 2023Review
- Investigation of the relationship between interferon-gamma receptor 1-56C/T gene polymorphism and genetic susceptibility to lung sarcoidosis: A cross-sectional study.Archives of rheumatology · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is an uncommon systemic inflammatory disorder characterized by noncaseating granulomatous inflammation that most commonly affects the lungs, intrathoracic lymph nodes, eyes and skin. One-third or more of patients with sarcoidosis have chronic, unremitting inflammation with progressive organ impairment. Findings of family and genetic studies indicate a genetic susceptibility to sarcoidosis, with genes in the MHC region having a dominant role. Immunologic hallmarks of the disease include highly polarized expression of cytokines produced by type 1 T helper cells and tumor necrosis factor (TNF) at sites of inflammation. Increasing evidence obtained within the past decade suggests the etiology of sarcoidosis predominantly involves microbial triggers, with the most convincing data implicating mycobacterial or propionibacterial organisms. Innate immune mechanisms, possibly involving misfolding and aggregation of serum amyloid A, might have a critical role in the pathobiology of sarcoidosis. Despite these advances, there are no clinically useful biomarkers that can assist the clinician in diagnosis, prognosis or assessment of treatment effects. Corticosteroids remain the cornerstone of therapy when organ function is threatened or progressively impaired. The role of immunosuppressive drugs and anti-TNF agents in the treatment of sarcoidosis remains uncertain, and there are no FDA-approved therapies. Meaningful progress in developing clinically useful tools and new therapies will depend on further advances in understanding the pathogenesis of sarcoidosis and its disease-specific pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.